



Candida parapsilosis Colony Morphotype Forecasts Biofilm
Formation of Clinical Isolates
Emilia Gómez-Molero 1,2, Iker De-la-Pinta 3, Jordan Fernández-Pereira 2, Uwe Groß 1, Michael Weig 1,




De-la-Pinta, I.; Fernández-Pereira, J.;
Groß, U.; Weig, M.; Quindós, G.;
de Groot, P.W.J.; Bader, O. Candida
parapsilosis Colony Morphotype
Forecasts Biofilm Formation of
Clinical Isolates. J. Fungi 2021, 7, 33.
https://doi.org/10.3390/jof7010033
Received: 8 December 2020
Accepted: 5 January 2021
Published: 7 January 2021
Publisher’s Note: MDPI stays neu-
tral with regard to jurisdictional clai-
ms in published maps and institutio-
nal affiliations.
Copyright: © 2021 by the authors. Li-
censee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and con-
ditions of the Creative Commons At-
tribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Institute for Medical Microbiology, University Medical Center Göttingen, Kreuzbergring 57,
37075 Göttingen, Germany; emiliagomez803@hotmail.com (E.G.-M.); ugross@gwdg.de (U.G.);
mweig@gwdg.de (M.W.)
2 Regional Center for Biomedical Research, Castilla-La Mancha Science & Technology Park,
University of Castilla–La Mancha, 02008 Albacete, Spain; Jordan.Fernandez@alu.uclm.es
3 Department of Immunology, Microbiology and Parasitology, School of Medicine and Nursing,
Universidad del País Vasco (UPV/EHU), 48940 Bilbao, Spain; iker.delapinta@ehu.eus (I.D.-l.-P.);
guillermo.quindos@ehu.eus (G.Q.)
* Correspondence: piet.degroot@uclm.es (P.W.J.d.G.); obader@gwdg.de (O.B.)
Abstract: Candida parapsilosis is a frequent cause of fungal bloodstream infections, especially in
critically ill neonates or immunocompromised patients. Due to the formation of biofilms, the use
of indwelling catheters and other medical devices increases the risk of infection and complicates
treatment, as cells embedded in biofilms display reduced drug susceptibility. Therefore, biofilm
formation may be a significant clinical parameter, guiding downstream therapeutic choices. Here,
we phenotypically characterized 120 selected isolates out of a prospective collection of 215 clinical
C. parapsilosis isolates, determining biofilm formation, major emerging colony morphotype, and
antifungal drug susceptibility of the isolates and their biofilms. In our isolate set, increased biofilm
formation capacity was independent of body site of isolation and not predictable using standard or
modified European Committee on Antimicrobial Susceptibility Testing (EUCAST) drug susceptibility
testing protocols. In contrast, biofilm formation was strongly correlated with the appearance of
non-smooth colony morphotypes and invasiveness into agar plates. Our data suggest that the
observation of non-smooth colony morphotypes in cultures of C. parapsilosis may help as an indicator
to consider the initiation of anti-biofilm-active therapy, such as the switch from azole- to echinocandin-
or polyene-based strategies, especially in case of infections by potent biofilm-forming strains.
Keywords: Candida parapsilosis; biofilm; colony morphology; drug susceptibility
1. Introduction
Candida parapsilosis was first described as a non-pathogenic yeast with no clinical rele-
vance [1]. However, increased use of medical devices, parenteral nutrition, and nosocomial
infections [2] has made C. parapsilosis one of the most critical fungal species causing blood
stream infections (BSI) [3], which are of particular relevance in critically ill neonates [4–6]
and immunocompromised patients [5,7].
The high infection rate with C. parapsilosis among neonates is likely due to the frequent
requirement of parenteral nutrition [8] and the concomitant ability of C. parapsilosis to utilize
fats and fatty acids as major energy sources [9]. In addition, the immature or compromised
immune system may favor infections with this species [10].
Another risk factor for acquiring C. parapsilosis infections is the use of indwelling
catheters and other medical devices onto which C. parapsilosis may form biofilms in con-
junction with other Candida species or bacteria [4]. Primarily, this is attributed to its capacity
to attach to the different materials of which medical devices are made [5,11,12]. This feature
is highly variable among individual clinical isolates [13]. In C. parapsilosis, the formation
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of biofilms is associated with the ability to form pseudohyphae [14–16] as well as the con-
comitant change in expression levels of cell wall-localized adhesins such as Als1-7 [17–19]
or Rbt1 [20]. Importantly, susceptibility to commonly used azole-based antifungal agents
in fungal biofilms on medical devices may be strongly reduced [21,22].
Similar to C. albicans (reviewed in [23]), C. parapsilosis can have different colony
morphotypes on diagnostic agar plates (Figure 1). While mixed-morphology culture plates
can be the result of infection with multiple strains [24] in diagnostic procedures, also, the
morphologic switching of some strains is a well-described phenomenon [25]. In addition
to their role in biofilm formation, pseudohyphae formation and adhesin expression are
also key to the visual appearance of fungal colonies on solid agars [26–28], which in turn
may well be correlated to the capacity to form biofilms in the host, the incorporation of cell
wall proteins (CWP), and, consequently, virulence [15].
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Figure 1. Colony morphotypes formed by C. parapsilosis. (A) Mixed morphotypes observed on a 
routine diagnostic plate. (B) Cells with distinct morphological colony phenotypes can be sub-cul-
tured, but some strains (here strain PEU582: smooth-glossy vs. crepe, see below) sometimes un-
dergo switching with strain-dependent frequencies. Smooth colonies are composed mainly of 
yeast-form cells, whereas non-smooth colonies are composed of pseudohyphal cells or mixtures of 
both morphologies. 
Here, we phenotypically characterized a large collection of clinical C. parapsilosis iso-
lates, including the description of novel intermediate morphotypes. We determined if 
Figure 1. Colony morphotypes formed by C. parapsilosis. (A) Mixed morphotypes observed on
a routine diagnostic plate. (B) Cells with distinct morphological colony phenotypes can be sub-
cultured, but some strains (here strain PEU582: smooth-glossy vs. crepe, see below) sometimes
undergo switching with strain-depend nt frequencies. Sm oth colonies are composed mainly of
yeast-form cells, wh reas non-smooth c lonies are composed of pseudohyphal cells or mixtures of
both morph logies.
H re, we phenotypically characterized a large collection of clinical C. parapsil sis
isolates, including the descripti n of novel intermediate morphotypes. We d termined if
early colony morphology was a potential predictor of biofilm production and pseudohyphal
growth and as such might reveal the need to direct the antifungal therapy against biofilms
containing C. parapsilosis.
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2. Materials and Methods
2.1. Clinical Routine Diagnostic and Strain Maintenance
C. parapsilosis clinical isolates were routinely identified using MALDI-TOF (MALDI
Biotyper, Bruker Daltonics, Bremen, Germany) according to the protocol described [29].
Mixed cultures were differentiated on YEPD agar (1% yeast extract, 2% peptone, 2% glucose,
2% agar) supplemented with 5 mg/mL phloxine B. On this medium, most tested colonies
developed a final morphotype within 48 h of incubation at 30 ◦C (Figure 1, Supplementary
Figures S1 and S2). Cells from colonies with stable morphotypes were transferred onto
Sabouraud dextrose agar (SDA, Oxoid, Munich, Germany), regrown, and stored at −70 ◦C
in cryovials (Mast Diagnostica, Reinfeld, Germany) for further analyses.
2.2. Biofilm Quantitation
Biofilm quantification assays on polystyrol were performed as described previously [11,30,31],
with adaptations to suit C. parapsilosis. Briefly, isolates were grown on phloxine B-containing
YEPD agar plates. Inoculum was prepared from single colonies grown to stationary phase
in YEPD broth at 30 ◦C overnight at 220 rpm. A cell suspension adjusted to a cell density
of McFarland = 2 was prepared using sterile saline, and 100 µL YEPD medium plus 50 µL
aliquots of the cell suspensions were mixed in 96-well polystyrol microtiter plates (Greiner
Bio-one) and incubated for 24 h at 37 ◦C. After removal of the medium by aspiration, the
attached biofilms were washed once with 200 µL of distilled water. Cells were stained
for 30 min in 100 µL of 0.1% aqueous crystal violet (CV). Excess CV was removed, and
the biofilm was washed once with 200 µL of distilled water. To release CV from the cells,
200 µL of 1% SDS in 50% ethanol was added, and the cellular material was resuspended by
pipetting. CV absorbance was quantified at 490 nm using a microtiter plate reader (MRX
TC Revelation). Data shown are the average of three independent biological experiments,
each including four technical repeats, using reference strain CDC317 as inter-experiment
quality control.
2.3. Antifungal Drug Susceptibility Testing
Susceptibility testing was performed according to EUCAST e.def 7.3.1 standards [32].
Fluconazole (FLZ), voriconazole (VRZ), posaconazole (POS), and amphotericin B (AMB)
substances were purchased from Discovery fine Chemicals Ltd. (Bournemouth, UK),
micafungin (MFG) was kindly provided by Astellas, and caspofungin (CAS) was provided
by Merck Sharp & Dohme Corp (MSD). Sequencing of the ERG11 and MRR1 genes was
performed as previously described [33].
Preformed biofilms reduction
Cells were pre-grown on Sabouraud dextrose agar (SDA) for 96 h at 30 ◦C, and one
colony was sub-cultured in 5 mL of YEPD broth overnight at 37 ◦C in an orbital incubator
at 200 rpm. Cells were harvested by centrifugation and resuspended in Phosphate-buffered
saline (PBS). Upon counting cells in a Neubauer chamber, the suspensions were adjusted
to 1 × 106 cells/mL in both RPMI (2 g/L glucose, pH 7) and YEPD (20 g/L glucose,
pH 6.7). One hundred µL of the inoculum was pipetted into each well of a Bioscreen plate
(Labsystem, Helsinki, Finland), and the plates were incubated for 24 h at 37 ◦C to allow
biofilm formation. Next, planktonic cells were removed, and the plates were washed twice
in PBS leaving just the biofilm in the wells. Two-fold serial dilutions of four antifungal
drugs were prepared in RPMI or YEPD ranging from 0.25 to 32 µg/mL for POS, VRZ, and
MFG, and from 0.0125 to 16 µg/mL for AMB. Subsequently, 100 µl of each dilution was
added to the corresponding wells with biofilm in triplicate, and the plates were incubated
again at 37 ◦C for 24 h. Finally, plates were washed twice with PBS, and reduction of
the biofilm metabolic activity was determined by measuring the absorbance at 492 nm
with the XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H- tetrazolium-5-carboxanilide)
colorimetric method [34].
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2.4. Morphotype Development and Agar Invasion
Selected C. parapsilosis isolates were cultured overnight in YEPD liquid media in an
orbital shaker at 220 rpm at 30 ◦C. Cell density was adjusted to 2 × 102 cells/mL, after
which 100 µL was plated onto YEPD agar plates and incubated at 30 ◦C for ten successive
days. Starting after 48 h, the morphotype development of colonies was captured every 24 h
over ten days using a stereoscopic binocular loupe (SZM-1, OPTIKA®, Ponteranica, Italy)
mounted with a digital camera. Morphotypes and agar invasion were classified according
to the references given in Supplementary Figure S1.
For analysis of agar invasion, colonies with different morphotypes were plated onto
YEPD agar plates supplemented with 5 mg/mL of phloxine B [25], and morphotype
development was followed as described above. Agar invasion was scored from day 4
onwards by scraping selected colonies with an inoculation loop and eventually washing
off the cells under running water on the last day. Agar invasion was classified as low (1),
low-medium (2), medium (3), medium-high (4), high (5), and finally as very high (6) when
cells could not be removed by rinsing (see scoring reference in Supplementary Figure S1).
2.5. Statistical Analyses
For statistical analyses of biofilms and antifungal drug susceptibility, unpaired two-
samples Student’s t-tests were used. All data used were the average of three independent
analyses, and p values < 0.05 were considered statistically significant.
To detect potential correlations between biofilm formation capacity, colony morpho-
type, and/or agar invasion capacity, regression analyses were performed, and Pearson’s
correlation coefficient r was used as a predictor for correlation. All data were analyzed
using IMB SPSS 22 statistics software.
3. Results
3.1. Biofilm Formation Capacity Is Independent of Body Site of Isolation
Over the course of two years, we collected 215 C. parapsilosis clinical isolates from our
routine diagnostics (Figure 2). Isolates were classified according to nine different categories
depending on the body site of isolation. C. parapsilosis is known to frequently occur in
the nape region, reaching up to the ear. Consequently, most isolates stemmed from ear
infections; however, a substantial number of isolates from invasive infections at other body
sites as well as from indwelling devices such as central venous or urine catheters were
included in the study. C. parapsilosis was only infrequently isolated from locations of the GI
(2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H- tetrazolium-5-carboxanilide) tract, the oral
cavity, or the skin.
Isolates obtained were systematically screened for their capacity to form biofilms in
standard biofilm formation tests in polystyrol microtiter plates. No body site, including
those isolate groups obtained from plastic materials, could be identified to be significantly
associated with elevated numbers of biofilm-forming isolates (p = 0.371, Figure 2A). When
stratified by quantitative measurement values, we observed a near even distribution across
the study group; only a tentative cut-off for low biofilm formation capacity was observed
at OD (optical density) measurement values of approximately 0.1 (Figure 2B, intersection
of black lines). Microscopical imaging of cells in biofilms from some representative isolates
confirmed the already established idea that the capacity to form biofilms is correlated with
pseudohyphal development (Supplementary Figure S3) [25–28].
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Figure 2. C. parapsilosis collection and selection of isolates for downstream experiments. (A) Dis-
tribution of collection isolates stratified according to site of isolation and biofilm production on
polystyrol. Category “invasive” includes, e.g., blood culture, biopsies, or intraoperative swabs.
Ora ge diamonds: six isolates used in pre-formed b ofilm experiments, see text. Red and green
lines: mean and two-fold mean values. (B) Biofilm formation capacity; isolates sorted by value from
low to high. Intersection of black lines: approximated cut-off. Red boxes indicate strain selection of
representative low (LBF, left box), intermediate (IBF, middle box) and high (HBF, right box) biofilm
formers for subsequent experiments.
3.2. Effect of Biofilm Formation on Antifungal Drug Susceptib lity
In order to estimate the correlation of the lead phenotype (biofilm formation on
polystyrol) with drug susceptibility, we selected 40 isolates each of low (LBF), intermediate
(IBF), and high (HBF) biofilm formation capacity (Figure 2B, red boxes) from our collection
including two non-adherent control strains (CDC317 and ATCC22019). The strains were
tested for susceptibility to selected azoles (FLZ, POS, VRZ), echinocandins (CAS, MFG),
and one polyene (AMB) after one (yo ng colonies) and eight days (matured colonies) of
growth on phloxine B agar plates.
Four IBF is lates (PEU651, PEU768, PEU941, nd PEU950), and reference strain
CDC317 showed el vated (minimum inhibitory conc ntration) MIC (values of 4–16 µg/mL
for FLC. To exclude potential biases through resistance mutations (e.g., Y132F [35]), we
sequ nced the ERG11 nd MRR1 genes in these isolates. A non-synonymous ERG11 point
mutation was found only in CDC317, which was heterozygous with respect to the Y132F
amino acid exchange. Y132F is known to confer resistance to fluconazole [36,37]. MRR1
only contained non-synonymous SNPs (Single nucleotide polymorphis s) in PEU651.
Since we could not exclude a potential influence of these mutations, data for PEU651
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as well as those of the two reference strains were excluded from the drug susceptibility
analysis, leaving a total of 117 isolates in three groups of 39 isolates each.
We did not observe large-scale differences in drug susceptibility between experiments
undertaken with young or mature colonies except for CAS (LBF p = 0.017 and HBF p = 0.028,
Figure 3A white vs. gray boxes).




Figure 3. Drug susceptibility. (A) Biofilm formation-phenotype dependent susceptibility testing where inoculum was pre-
pared from cells after 1 day of growth on Sabouraud dextrose agar (SDA) (gray boxes) and after 8 days of growth (white 
boxes) on the same plates, when colonies had fully developed morphotypes. For each substance tested, the values for 1 
and 8-day inoculum are depicted for each group (LBF, IBF, and HBF). Red lines: EUCAST clinical breakpoint (R>); green 
lines, susceptible cut-off (S ≤). *: statistical significance (B,C) Effect of antifungal drugs on cell viability in pre-formed 
biofilms of selected biofilm-forming isolates tested in (B) RPMI (Roswell Park Memorial Institute )or (C) YEPD(yeast ex-
tract peptone dextrose) media. 
3.3. Susceptibility of Biofilms to Antifungal Drugs 
Next, for six selected intermediate to high biofilm-forming isolates, we analyzed to 
which degree pre-formed C. parapsilosis biofilms resisted antifungal drug treatment in two 
different media, RPMI and YEPD. RPMI is considered the reference medium for antifun-
gal drug susceptibility testing and, as mentioned above, it was also used for MIC deter-
mination according to the EUCAST protocol. Likewise, YEPD is a glucose-rich medium 
that is widely used in assays with yeasts due to the large amount of peptone and dextrose 
extremely necessary for yeast growth and biofilm formation. The ability to form biofilms 
. Drug susceptib lity. (A) Biofilm formation-phenotype dependent suscept bility testing where inoculum was
repared from cells after 1 day of growth on Sabourau dextrose agar (SDA) (gray boxes) and after 8 days of r t
boxes) on the sa e plates, when colonies had fully developed morphotypes. For each substance tested, the values for 1 and
8-day inoculum are depicted for each group (LBF, IBF, and HBF). Red lines: EUCAST clinical breakpoint (R>); green lines,
susceptible cut-off (S ≤). *: statistical significance (B,C) Effect of antifungal drugs on cell viability in pre-formed biofilms of
selected biofilm-forming isolates tested in (B) RPMI (Roswell Park Memorial Institute )or (C) YEPD(yeast extract peptone
dextrose) media.
Although statistically significant differences between HBF versus IBF or LBF isolate
groups were clearly evi ent for some antifungal drugs (POS: LBF vs. HBF with young
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colonies p = 0.014, mature colonies p = 0.072, CAS: LBF vs. HBF with young colonies
p = 0.015), the observed mean MIC differences did not result in a major change in classifica-
tion of either susceptible (S) or resistant (R) according to EUCAST breakpoints. Differences
in mean susceptibility values were 1-2 log2-fold decreases for VRZ, POS (mature colonies
only), CAS, and MFG in the HBF group, as compared to the LBF group. No apparent
differences for either FLZ or AMB were seen.
3.3. Susceptibility of Biofilms to Antifungal Drugs
Next, for six selected intermediate to high biofilm-forming isolates, we analyzed
to which degree pre-formed C. parapsilosis biofilms resisted antifungal drug treatment
in two different media, RPMI and YEPD. RPMI is considered the reference medium for
antifungal drug susceptibility testing and, as mentioned above, it was also used for MIC
determination according to the EUCAST protocol. Likewise, YEPD is a glucose-rich
medium that is widely used in assays with yeasts due to the large amount of peptone
and dextrose extremely necessary for yeast growth and biofilm formation. The ability
to form biofilms was evaluated using this culture medium. Since both media are widely
used in the literature, we decided to test the drug susceptibility of preformed biofilms in
both of them, observing that some strains are more prone to form biofilms in one media
and not in the other, as well as behaving differently when interacting with antifungal
drugs. More specifically, one of the six isolates (PEU651) was not able to form biofilm in
RPMI (Figure 3B), whereas another (PEU582) grew only at reduced rates. Both isolates also
showed a reduction in biofilm development in YEPD (Figure 3C) but were kept in these
assays as the results were qualitatively in agreement with the other strains used.
Antifungal drugs had different quantitative effects when the assay was carried out in
RPMI (Figure 3B) or in YEPD (Figure 3C). In YEPD, sub-inhibitory drug concentrations
caused increases in metabolic activity, as measured by XTT reduction. This may be a
stress-response effect countering drugs at these levels, and it was considered an artifact
for the purpose of this study. Higher concentrations of azoles (POS, VRZ) reduced biofilm
metabolic activity by only 30–50% as compared to the drug-free control. There was no azole
drug concentration in the measurement range (up to 32 µg/mL) that led to a full reduction
in biofilm metabolic activity (all p > 0.05). In contrast, both MFG and AMB did achieve a
strong reduction of metabolic activity, although under different conditions: in RPMI, an
AMB concentration of 0.5 µg/mL was sufficient for 70% reduction, while 16 µg/mL were
required in YEPD. For MFG, this was the opposite: in YEPD, a clear effect was seen at
2 µg/mL with only residual metabolic activity apparent up to the upper assay boundaries
(32 µg/mL).
3.4. Biofilm Formation Capacity on Polystyrol Correlates with Colony Morphotype and
Agar Invasiveness
On culture plates, individual C. parapsilosis isolates showed specific, stable morpho-
types. Only a minority of isolates (18%) were also able to switch between such morphotypes
upon re-plating (Figure 1 and scoring reference shown in Supplementary Figure S1).
In a preliminary analysis on a selected subset (Supplementary Figure S2), non-smooth
colony morphologies were already apparent at the start of the observation period (20%)
and reliably appeared after 72 h of growth. Across the entire collection, agar invasion
(Supplementary Figure S1A) and colony morphotype (Supplementary Figures S1B and S2)
were therefore scored over a course of four to ten days (Figure 4). Most LBF isolates (90%)
showed smooth morphotypes, and only a small proportion (10%), for instance PEU944,
developed wrinkled or crepe phenotypes. On day 10, about 20% had developed non-
smooth morphotypes as their major morphology (Figure 4A). With increasing biofilm
formation capacity, also the frequency of non-smooth colony morphotypes increased. Of
the IBF isolates, 20% had developed non-smooth morphotypes at day 4, and 55% had
developed non-smooth morphotypes on day 10. HBF isolates mainly, but not exclusively,
produced non-smooth phenotypes (66% on day 4, 83% on day 10), which in most cases
were already distinguishable at day 2. Some isolates presented two independent stable
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morphotypes (e.g., PEU525: non-smooth (cr) and smooth (s)), which were distinguishable
from day 2 until day 10. Along with the increased formation of non-smooth colony
morphotypes in IBF and HBF strains (r = 0.832, p < 0.001), also agar invasiveness increased
from day 4 to day 10 (r = 0.969, *** p < 0.001 (Figure 4B, Table 1).




Figure 4. Emergence of colony morphotype over time. (A) Development of colony morphotype 
and (B) agar invasiveness scoring the same plates consecutively from 4 days to 10 days after inoc-
ulation. Isolates with low biofilm formation capacity (left panels), intermediate biofilm formation 
capacity (middle panels), and high biofilm formation capacity (right panels) were scored for the 
most frequent colony morphotype visible. Of note, HBF isolates rated “smooth” still developed 
minor frequencies of non-smooth colonies. See Supplementary Figure S1 for scoring references. 
Table 1. Agar invasiveness and colony morphology. 
Morphology a n Agar Invasion 
a 
Low Low-Medium Medium Medium-High High Very High 
smooth 59 34% 27% 5% 32% 2% 0% 
wrinkled 22 5% 9% 23% 50% 9% 5% 
mixed/infrequent 16 0% 6% 6% 63% 19% 6% 
crepe I and II 25 4% 4% 0% 36% 28% 28% 
a see Supplementary Figure S1 for classification of agar invasion and morphotypes. 
4. Discussion 
C. parapsilosis is frequently found as a cause of pathologies due to biofilm formation 
on medical devices in long-term hospitalized patients suffering from endocarditis, perito-
nitis, arthritis, or general sepsis [22,38–40]. We hypothesized that the capacity to form bio-
film might be related to the origin of the clinical specimen, that is, infections at different 
body sites or fungus growing on medical devices such as indwelling catheters. However, 
Figure 4. Emergence of colony morphotype over time. (A) Development of colony morphotype and (B) agar invasiveness
scoring the same plates consecutively from 4 days to 10 days after inoc lation. Is lates with low biofilm formation capacity
(left panels), intermediate biofilm f rmation capacity (middle panels), and high biofilm formation capacity (right panels)
were scored for the most frequent colony morp otype visible. Of ote, HBF isolates rated “smooth” still developed minor
frequencies of non-smooth colonies. See Supplementary Figure S1 for scoring references.
Table 1. Agar invasiveness and colony morphology.
Morphology a n Agar Invasion
a
Low Low-Medium Medium Medium-High High Very High
smooth 59 34% 27% 5% 32% 2% 0%
wrinkled 22 5% 9% 23% 50% 9% 5%
mixed/infrequent 16 0% 6% 6% 63% 19% 6%
crepe I and II 25 4% 4% 0% 36% 28% 28%
a see Supplementary Figure S1 for classification of agar invasion and morphotypes.
4. Discussion
C. parapsilosis is frequently found as a cause of pathologies due to biofilm formation on
medical d vices in l ng-term hospitalized patients suff ring from endoc rditis, peritonitis,
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arthritis, or general sepsis [22,38–40]. We hypothesized that the capacity to form biofilm
might be related to the origin of the clinical specimen, that is, infections at different body
sites or fungus growing on medical devices such as indwelling catheters. However, when
the 215 clinical isolates in our collection were scored for their biofilm-forming capacity on
rich medium (YEPD), a strong inducer of biofilms in C. parapsilosis [41], no clear distribution
of low (LBF) versus high (HBF) biofilm formation depending on the site of isolation was
detected. Nevertheless, a high percentage of catheter-associated isolates belonged to the
IBF and HBF groups, which is consistent with the notion that C. parapsilosis infections often
start from infected indwelling devices [42,43].
Then, we raised the question of whether there might be a possible link between the
biofilm-forming capacity of clinical isolates and their drug susceptibility [21,22], which
could be useful for decision making about treatment strategies in the clinic. However,
tests with the three groups of isolates (LBF, IBF, and HBF), reflecting a wide range—from
negligible to high quantities of biomass—of biofilm-formation capacity on polystyrol, and
six commonly used azole-, echinocandin-, and polyene antifungal agents did not reveal
any such correlation. Observed MIC values were similar to those reported previously
by others [44–47], and also, no remarkable differences were observed between inocula
prepared from young or matured cells (as found in biofilms). Therefore, we conclude that
the drug susceptibility data obtained with the standard EUCAST protocol do not seem to
generate predictive information toward the biofilm-formation capacity of clinical isolates.
Nevertheless, fungal cells embedded within biofilms, including those formed by C.
parapsilosis, are considered to be less susceptible to antifungal compounds [21,22]. This
notion was confirmed here by studying the antifungal drug susceptibility of six biofilm-
forming strains embedded in preformed biofilms, which showed significantly reduced
sensitivity to azoles. This experiment was executed in both YEPD (high glucose) and RPMI
(lower glucose) medium. As expected [41], biofilm formation in YEPD was higher than in
RPMI, and media-dependent differences in echinocandin and polyene sensitivity were also
noted. These observations support earlier reported overall quantitative dependences of
biofilm formation and drug susceptibility on glucose levels in the media [41,48,49].
Another important aspect of our study was the question of whether C. parapsilosis
colony morphotypes might perhaps serve to forecast the biofilm-forming capacity of
clinical isolates. We hypothesized that high biofilm formers would show more non-smooth
morphotypes and pseudohyphae than poor biofilm formers and have an increased tendency
to invade agar [50]. When following colony morphotype development in the three isolate
groups (LBF, IBF, and HBF) over a course of ten days, we indeed observed a strong
correlation of the HBF group with non-smooth colony morphotypes. In contrast, the
appearance of non-smooth colonies occurred only in a minority of the isolates in the LBF
group. As surface adherence represents the first step in biofilm formation, our data are
supported by studies showing that non-smooth colonies are generally more adherent to
plastic than smooth colonies [51].
Interestingly, in most cases, non-smooth morphotypes could already be observed
within 48 h of growth, and only little change was observed after 96 h, indicating that
prolonged incubation beyond this time point is not needed for morphotype determination.
In addition, all the morphotypes appeared stable, as they were reproduced upon repeating
the experiment, which is consistent with the idea that switching is not a common or
frequent event. Finally, biofilm-forming capacity and the appearance of non-smooth
morphotypes and pseudohyphae were positively correlated to agar invasion. However, a
large proportion of smooth colony types also displayed medium-strength agar invasion,
indicating pseudohyphae formation at least at the base of the colony [52,53].
In summary, our experiments show that there is a strong correlation between colony
morphotype and biofilm formation capacity in isolates from clinical samples and that this
is not reflected in the results from standard antifungal drug susceptibility testing. Our
data are the first to indicate that the observation of non-smooth colony morphotypes of
C. parapsilosis may help to consider the initiation of anti-biofilm-active therapy. This may
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include antifungal lock therapy and shifting treatment from azole-based to echinocandin-
or polyene-based strategies to eliminate biofilms from catheters [39]. However, due to the
inherent ability of some strains to switch between morphotypes [25–28,54], the absence
of such colonies should not be taken as an absolute indicator that biofilms do not exist in
the patient.
Supplementary Materials: The following are available online at https://www.mdpi.com/2309-6
08X/7/1/33/s1, Supplementary Figure S1. Morphological classification of C. parapsilosis colony
morphotypes. (A) Semi-quantitative classification of agar invasion on phloxine B-containing SDA. (B)
Colony morphotypes observed in our isolate collection. In picture pairs, left pictures represent colony
morphotype after 10 d incubation, right pictures show agar imprint left on phloxine B agar plates
after flushing off colonies with running water. Scale bars = 0.25 cm; Supplementary Figure S2. Colony
morphotype development during a ten-day time-lapse experiment. Morphotype development of
colonies was followed during ten days of growth on YEPD agar at 30 ◦C. (A) Five selected low
biofilm-forming (LBF) clinical isolates, (B) five intermediate biofilm-forming (IBF) isolates, and
(C) five high-biofilm-forming (HBF) isolates. d, derby; cn, concentric; cr, crater; s, smooth; wr,
wrinkled; Supplementary Figure S3. Morphology of C. parapsilosis cells in biofilms onto polystyrol.
Representative strains with low (LBF, row 1), intermediate (IBF, row2), and high (HBF, rows 3 and 4)
biofilm formation capacity are shown. Biofilms were let to develop for 24 h in YEPD as described in
materials and methods. Unbound cells were removed by washing with PBS. Remaining biofilm cells
were observed with a Leica DM1000 microscope mounted with a HC PL 100×/1.32 objective and
MC170 HD digital camera.
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